Table 3 Concomitant cardiovascular illnesses and risk factors in the overall population
| Â | Â | Â | Cariporide | ||
|---|---|---|---|---|---|
| Â | All (n=11 587) | Placebo (n=2909) | 20 mg (n=2908) | 80 mg (n=2887) | 120 mg (n=2883) |
Median age (years) | 66.0 | 65 | 66 | 66 | 66 |
Sex (% male) | 69.9 | 70.0 | 70.2 | 69.3 | 69.9 |
Smoking status (%) | Â | Â | Â | Â | Â |
   Current | 22.8 | 23.7 | 22.1 | 23.0 | 22.5 |
   Ex smoker | 44.7 | 44.6 | 45.1 | 44.4 | 44.6 |
   MI at study entry (%) | 10.4 | 10.0 | 11.1 | 10.4 | 10.1 |
History of (%) | Â | Â | Â | Â | Â |
   Stable angina | 24.1 | 23.8 | 23.9 | 23.6 | 25.0 |
   Unstable angina | 58.8 | 58.0 | 59.9 | 59.4 | 58.0 |
   MI | 44.5 | 44.0 | 45.4 | 44.6 | 43.9 |
   Congestive heart failure | 7.7 | 7.1 | 8.3 | 7.4 | 7.9 |
   Hypertension | 53.1 | 51.8 | 53.7 | 53.3 | 53.5 |
   Cerebrovascular disease | 6.1 | 5.4 | 6.0 | 6.2 | 6.7 |
   Peripheral vascular disease | 13.5 | 12.9 | 13.9 | 13.9 | 13.1 |
   Cardiac arrhythmia | 12.2 | 11.7 | 13.0 | 11.5 | 12.4 |
   Hypercholesterolemia | 55.0 | 54.3 | 55.1 | 55.9 | 54.8 |
   NIDDM | 19.7 | 19.2 | 20.2 | 20.5 | 18.9 |
   IDDM | 7.1 | 6.1 | 7.2 | 7.1 | 8.0 |